Advertisement

PET-Studien zur Dopaminrezeptorbindung bei neuroleptisch behandelten Patienten

  • L. Farde

Zusammenfassung

Die antipsychotische Wirkung von Neuroleptika ist gut belegt. Die weithin anerkannte Hypothese zur Wirkungsweise von Antipsychotika besagt, daß der Effekt der Neuroleptika in Beziehung steht zu ihrer Fähigkeit, den Neurotransmitter Dopamin zu antagonisieren (Carlsson u. Lindqvist 1963; van Rossum 1966). Die Entwicklung von Radioligandenbindungstechniken und die Verfügbarkeit 3H-markierter Neuroleptika ermöglichte die Untersuchung der Bindungsstellen für Neuroleptika in Hirnhomogenaten und Hirnschnitten. Erhärtet wurde die Dopaminhypothese durch den Nachweis einer linearen Korrelation zwischen der an Tierhirnen in vitro ermittelten Affinität einer Substanz für den D2-Subtyp des Dopaminrezeptors und ihrer klinischen antipsychotischen Wirksamkeit beim Menschen (Creese et al. 1976; Seeman et al. 1976).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andersen PH (1988) Comparison of the pharmacolocical characteristics of [3H]raclopride and [3H]SCH-23390 binding to dopamine receptors in vivo mouse brain. Eur J Pharmacol 146: 113–120PubMedCrossRefGoogle Scholar
  2. Cambon H, Baron JC, Boulenger JP, Loch C, Zarifian E, Mazière B (1987) In vivo assay for neuroleptic receptor binding in the striatum. Br J Psychiatry 151: 824–830PubMedCrossRefGoogle Scholar
  3. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140–144CrossRefGoogle Scholar
  4. Creese L, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483PubMedCrossRefGoogle Scholar
  5. Farde L (1992) Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans — a PET study with [11C]SCH-23390 and [11C]raclopride. Psychopharmacology 107: 23–29PubMedCrossRefGoogle Scholar
  6. Farde L, Hall H, Ehrin E, Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231: 258–261PubMedCrossRefGoogle Scholar
  7. Farde L, Halldin C, Stone-Elander S, Sedvall G (1987) PET analysis of human dopamine receptor subtypes using 11C-SCH-23390 and 11C-raclopride. Psychopharmacology 92: 278–284PubMedCrossRefGoogle Scholar
  8. Farde L, Wiesel F-A, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76PubMedGoogle Scholar
  9. Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992 a, b) PET-analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544Google Scholar
  10. Hyttel J (1983) SCH 13390 — the first selective dopamine DI antagonist. Eur J Pharmacol 91: 153–154PubMedCrossRefGoogle Scholar
  11. Kane J, Honicfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796PubMedGoogle Scholar
  12. Köhler C, Hall H, Ogren SO, Gawell L (1985) Specific in vitro and in vivo binding of 3Hraclopride, a potent substituted drug with high affinity for dopamine D2 receptors in the rat brain. Biochem Pharmacol 34: 2251–2259PubMedCrossRefGoogle Scholar
  13. Nordström A, Farde L, Wiesel F, Forslund K, Pauli S, Halldin C (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug-effects: double blind study of schizophrenic patients. Biol Psychiatry 33: 227–235PubMedCrossRefGoogle Scholar
  14. Rossum JM van (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn 160: 492–494PubMedGoogle Scholar
  15. Sedvall G, Farde L, Persson A, Wiesel F-A (1986) Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatr 43: 995–1005PubMedGoogle Scholar
  16. Seeman P, Lee T, Chau-Wong, M, Wong K (1976) Antipsychotic drug doses and neuroleptic dopamine receptors. Nature 261: 717–719PubMedCrossRefGoogle Scholar
  17. Smith M, Wolf A, Brodie J, Amett C, Barouche F, Shiue C, Fowler J, Russel J, MacGregor R, Wolkin A (1988) Serial [18 F] N-methylspiperone PET-studies to measure chances in antipsychotic drug, D2 receptor occupancy in schizophrenic patients. Biol Psychiatry 23: 653–663PubMedCrossRefGoogle Scholar
  18. Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika — anhand von pharmakologischen und klinischen Befunden mit Clozapin. Pharmacopsychiatry 4: 188–191CrossRefGoogle Scholar
  19. Wagner HNJ, Burns HD, Dannals RF, Wonc et al. (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221: 1264–1266PubMedCrossRefGoogle Scholar
  20. Wonc, D, Gjedde A, Wagner H Jr (1986a) Quantification of neuroreceptors in the living human brain I. Irreversible binding of ligands. J Cereb Blood Flow Metab 6: 137–146CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • L. Farde

There are no affiliations available

Personalised recommendations